On Wednesday, October 18, 2017, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) supported, by a vote of 16-Yes to 0-No, with one abstention, the safety and efficacy of semaglutide injection, submitted by Novo Nordisk, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.